Literature DB >> 8369118

Influence of LAK cells on expression of HLA-DR antigen on laryngeal carcinoma cell line in new culture systems.

H Kumazawa1, T Kumazawa, T Tachikawa, S Sai, T Yamashita, K Kawamoto.   

Abstract

We demonstrated the enhancement of HLA-DR antigen expression on cultured laryngeal carcinoma cells (Hep 2) by in vitro cultivation with LAK cells using flow cytometric and immunohistological analysis. For in vitro cultivation of tumor cells with LAK cells, we used newly developed experimental systems (the Transwell double-dish system and experimental three-dimensional tumors). In flow cytometric analysis, expression of HLA-DR antigen on tumor cells was compared before and after co-cultivation with LAK cells. When tumor cells were cultured separately with LAK cells in a Transwell Petri dish and the expression of HLA-DR antigen on tumor cells was analyzed by flow cytometry, the expression of HLA-DR antigen on tumor cells was increased in a dose-dependent manner related to the number of LAK cells used. Furthermore, when anti-interferon-gamma monoclonal antibody was added to the experimental system, enhancement of HLA-DR antigen expression was blocked. These findings were consistent with immunohistological studies, in which experimental three-dimensional Hep 2 cell tumors were established in double-layered agar with/without being co-cultivated with LAK cells. The expression of HLA-DR antigen in this system was significantly increased when compared to such expression before cultivation with LAK cells. These findings suggested that the culture systems employed in this study could be a possible model for examining solid tumor in vivo biological responses. This enhanced expression of HLA-DR antigen may also represent one of the multi-factorial responses seen with adoptive LAK cell immunotherapy for solid tumors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8369118     DOI: 10.1007/bf00171529

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  24 in total

1.  Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.

Authors:  E A Wiebke; M C Custer; S A Rosenberg; M T Lotze
Journal:  J Biol Response Mod       Date:  1990-04

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  The anti-tumor effect of in vitro tumor-stimulated autologous peripheral blood lymphocytes measured by the subrenal capsule assay.

Authors:  C Kürten; R Kau; H Kumazawa; P Koldovsky
Journal:  Arch Otorhinolaryngol       Date:  1989

4.  Morphologic analysis of three-dimensional tumors developed in fibrin matrix and agar culture system.

Authors:  H Kumazawa; M Hess; P Koldovsky
Journal:  Pathobiology       Date:  1993       Impact factor: 4.342

5.  Antineoplastic effects of natural killer cells sorted with flow cytometry on brain tumors.

Authors:  K Kawamoto; H Fujiwara; Y Numa; H Matsumura
Journal:  Hum Cell       Date:  1991-06       Impact factor: 4.174

6.  [Establishing three dimensional tumors in vitro and the reaction of the lymphokine-activated killer cells (LAK) to the three dimensional tumors].

Authors:  H Kumazawa; P Koldovsky; C Kürten; M Hess; S Tujikawa; K H Vosteen
Journal:  Auris Nasus Larynx       Date:  1991       Impact factor: 1.863

7.  Phenotypic dynamics of tumor progression in human malignant melanoma.

Authors:  E B Bröcker; L Suter; J Brüggen; D J Ruiter; E Macher; C Sorg
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

8.  The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells.

Authors:  D Taramelli; G Fossati; A Balsari; R Marolda; G Parmiani
Journal:  Int J Cancer       Date:  1984-12-15       Impact factor: 7.396

9.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Authors:  M T Lotze; Y L Matory; S E Ettinghausen; A A Rayner; S O Sharrow; C A Seipp; M C Custer; S A Rosenberg
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

10.  Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.

Authors:  H O Wintzer; M Benzing; S von Kleist
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.